Alpha-9 Theranostics announces oversubscribed US$75 million Series B financing
On December 14, 2022, Alpha-9 Theranostics Inc. (“Alpha-9”) announced an oversubscribed US$75 million Series B financing to advance its portfolio of radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer.
The round was led by Nextech Invest, with participation from Frazier Life Sciences, Samsara BioCapital and QV Global Health Sciences Fund in addition to existing investors Longitude Capital and BVF Partners.
In addition to advancing its clinical pipeline, the Series B will enable Alpha-9 to grow its team to support discovery programs.
Further information can be found on PR Newswire’s website.
Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer.